{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:51:51Z","timestamp":1787791911999,"version":"build-2784847793"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jsat.2021.108407","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T03:02:50Z","timestamp":1618542170000},"page":"108407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Extended-release naltrexone for youth with opioid use disorder"],"prefix":"10.1016","volume":"130","author":[{"given":"Shannon Gwin","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Monico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Gryczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.","family":"O'Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jsat.2021.108407_bb0005","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/TA.0000000000002261","article-title":"Long-term prescription opioid utilization, substance use disorders, and opioid overdoses after adolescent trauma","volume":"87","author":"Bell","year":"2019","journal-title":"Journal of Trauma and Acute Care Surgery"},{"key":"10.1016\/j.jsat.2021.108407_bb0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.drugalcdep.2018.02.023","article-title":"Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial","volume":"187","author":"Bisaga","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.jsat.2021.108407_bb0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/ADM.0000000000000388","article-title":"Buprenorphine treatment for adolescents and young adults with opioid use disorders: A narrative review","volume":"12","author":"Borodovsky","year":"2018","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2021.108407_bb0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.15288\/jsad.2019.80.393","article-title":"Medications for maintenance treatment of opioid use disorder in adolescents: A narrative review and assessment of clinical benefits and potential risks","volume":"80","author":"Camenga","year":"2019","journal-title":"J Stud Alcohol Drugs"},{"issue":"3","key":"10.1016\/j.jsat.2021.108407_bb0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jpeds.2015.04.071","article-title":"Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: A national study","volume":"167","author":"Cerda","year":"2015","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jsat.2021.108407_bb0030","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders","volume":"138","author":"Committee on Substance Use and Prevention","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jsat.2021.108407_bb0035","doi-asserted-by":"crossref","first-page":"108076","DOI":"10.1016\/j.jsat.2020.108076","article-title":"A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder","volume":"117","author":"Farabee","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.jsat.2021.108407_bb0040","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jadohealth.2016.12.023","article-title":"Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder","volume":"60","author":"Feder","year":"2017","journal-title":"The Journal of Adolescent Health"},{"issue":"6","key":"10.1016\/j.jsat.2021.108407_bb0045","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jadohealth.2020.07.038","article-title":"Young adults have worse outcomes than older adults: Secondary analysis of a medication trial for opioid use disorder","volume":"67","author":"Fishman","year":"2020","journal-title":"The Journal of Adolescent Health"},{"key":"10.1016\/j.jsat.2021.108407_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/add.15181","article-title":"A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder","author":"Fishman","year":"2021","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.jsat.2021.108407_bb0055","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1360-0443.2010.03015.x","article-title":"Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: Preliminary case-series and feasibility","volume":"105","author":"Fishman","year":"2010","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jsat.2021.108407_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0217","article-title":"The burden of opioid-related mortality in the United States","volume":"1","author":"Gomes","year":"2018","journal-title":"JAMA Network Open"},{"issue":"11","key":"10.1016\/j.jsat.2021.108407_bb0065","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and Association of Early Medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.jsat.2021.108407_bb0070","doi-asserted-by":"crossref","first-page":"106226","DOI":"10.1016\/j.addbeh.2019.106226","article-title":"Optimism and opioid misuse among justice-involved children","volume":"103","author":"Johnson","year":"2020","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2021.108407_bb0075","article-title":"Monitoring the future National Survey Results on drug use, 1975-2018: Overview, key findings on adolescent drug use","author":"Johnston","year":"2019","journal-title":"Ann Arbor: Institute for Social Research, University of Michigan."},{"issue":"13","key":"10.1016\/j.jsat.2021.108407_bb0080","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"10118","key":"10.1016\/j.jsat.2021.108407_bb0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jsat.2021.108407_bb0090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jama.2018.6566","article-title":"Increasing fatality rates from preventable deaths in teenagers and young adults","volume":"320","author":"Lee","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jsat.2021.108407_bb0095","article-title":"Medication-assisted treatment of adolescents with opioid use disorders","volume":"138","author":"Levy","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jsat.2021.108407_bb0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000313336","article-title":"Naltrexone implants compared to methadone: Outcomes six months after prison release","volume":"16","author":"Lobmaier","year":"2010","journal-title":"European Addiction Research"},{"issue":"1","key":"10.1016\/j.jsat.2021.108407_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/16066350802531273","article-title":"Treatment research in prison: Problems and solutions in a randomized trial","volume":"18","author":"Lobmaier","year":"2010","journal-title":"Addiction Research & Theory"},{"issue":"6","key":"10.1016\/j.jsat.2021.108407_bb0110","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/ajad.12763","article-title":"Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone","volume":"27","author":"Mannelli","year":"2018","journal-title":"The American Journal on Addictions"},{"issue":"10","key":"10.1016\/j.jsat.2021.108407_bb0115","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial","volume":"62","author":"Marsch","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1016\/j.jsat.2021.108407_bb0120","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/add.13363","article-title":"A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults","volume":"111","author":"Marsch","year":"2016","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.jsat.2021.108407_bb0125","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/ADM.0000000000000035","article-title":"A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine\/naloxone clinic","volume":"8","author":"Matson","year":"2014","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2021.108407_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0b013e3181d916db","article-title":"HIV risk behavior in treatment-seeking opioid-dependent youth: Results from a NIDA clinical trials network multisite study","author":"Meade","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jsat.2021.108407_bb0135","article-title":"Maintenance treatments for opiate -dependent adolescents","volume":"6","author":"Minozzi","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1016\/j.jsat.2021.108407_bb0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40272-013-0041-5","article-title":"Pharmacologically assisted treatment of opioid-dependent youth","volume":"15","author":"Pecoraro","year":"2013","journal-title":"Paediatric Drugs"},{"issue":"3","key":"10.1016\/j.jsat.2021.108407_bb0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jsat.2014.04.006","article-title":"Emerging adult age status predicts poor buprenorphine treatment retention","volume":"47","author":"Schuman-Olivier","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108407_bb0150","doi-asserted-by":"crossref","first-page":"107680","DOI":"10.1016\/j.drugalcdep.2019.107680","article-title":"Methadone treatment of arrestees: A randomized clinical trial","volume":"206","author":"Schwartz","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108407_bb0155","series-title":"Measuring alcohol consumption","first-page":"41","article-title":"Timeline follow-back","author":"Sobell","year":"1992"},{"issue":"5","key":"10.1016\/j.jsat.2021.108407_bb0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11920-009-0054-5","article-title":"Treatment of opioid-dependent adolescents and young adults with buprenorphine","volume":"11","author":"Subramaniam","year":"2009","journal-title":"Current Psychiatry Reports"},{"issue":"5","key":"10.1016\/j.jsat.2021.108407_bb0165","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine","volume":"174","author":"Sullivan","year":"2017","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2021.108407_bb0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpsychires.2015.11.003","article-title":"Racial and ethnic trends and correlates of non-medical use of prescription opioids among adolescents in the United States 2004-2013","volume":"73","author":"Vaughn","year":"2016","journal-title":"Journal of Psychiatric Research"},{"issue":"9","key":"10.1016\/j.jsat.2021.108407_bb0175","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.addbeh.2012.04.011","article-title":"Predictors of attrition with buprenorphine\/naloxone treatment in opioid dependent youth","volume":"37","author":"Warden","year":"2012","journal-title":"Addictive Behaviors"},{"issue":"1","key":"10.1016\/j.jsat.2021.108407_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jadohealth.2020.04.002","article-title":"Medication treatment for opioid-addicted youth-what are we waiting for?","volume":"67","author":"Woody","year":"2020","journal-title":"The Journal of Adolescent Health"},{"issue":"17","key":"10.1016\/j.jsat.2021.108407_bb0185","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial","volume":"300","author":"Woody","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2021.108407_bb0190","author":"World Health Organization (WHO)"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:54:07Z","timestamp":1760039647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221001331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":38,"alternative-id":["S0740547221001331"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108407","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended-release naltrexone for youth with opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108407"}}